ARTV - Artiva Biotherapeutics Inc
NYSE * Health Care * Biotechnology
$10.80
+$0.56 (+5.47%)
About Artiva Biotherapeutics Inc
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.
ARTV Key Statistics
Market Cap
$253.10M
P/B Ratio
2.30
EPS
$-3.43
Revenue Growth
-1.0%
Employees
104
How ARTV Compares to Peers
P/E Rank
N/A
of 5
Margin Rank
N/A
of 5
Growth Rank
#6
of 6
Size Rank
#6
of 6
Artiva Biotherapeutics Inc Company Information
- Headquarters
- California; U.S.A
- Website
- www.artivabio.com
- Sector
- Health Care
- Industry
- Biotechnology